CNNM2 Antibody

What is CNNM2 and why is it significant in scientific research?

CNNM2 (Cyclin M2) is a divalent metal cation transporter primarily expressed in the brain and distal convoluted tubule (DCT) of the kidney. Its significance stems from its crucial role in magnesium homeostasis and brain development. CNNM2 mediates transport of divalent metal cations in a preferential order of Mg²⁺ > Co²⁺ > Mn²⁺ > Sr²⁺ > Ba²⁺ > Cu²⁺ > Fe²⁺ . Mutations in the CNNM2 gene have been associated with hypomagnesemia, seizures, and intellectual disability (HSMR syndrome) . The protein contains important domains including cystathionine β-synthase (CBS) domains that are essential for its function and interaction with Mg²⁺-ATP .

What are the validated applications for CNNM2 antibodies in research?

CNNM2 antibodies have been validated for multiple applications including:

• Western blotting (WB): Detecting CNNM2 expression levels in cell or tissue lysates

• Immunocytochemistry and immunofluorescence (ICC-IF): Visualizing CNNM2 localization within cells

• Immunohistochemistry (IHC): Examining CNNM2 expression patterns in tissue sections

Most commercially available CNNM2 antibodies are validated for detection in human, mouse, and rat samples, with some antibodies also recognizing the protein in other species including bovine, canine, equine, and zebrafish models .

How can I confirm the specificity of my CNNM2 antibody?

To confirm antibody specificity:

• Include positive controls (tissues/cells known to express CNNM2, such as kidney DCT cells or brain tissue)

• Include negative controls (tissues with minimal CNNM2 expression or CNNM2 knockout samples)

• Perform siRNA knockdown of CNNM2 followed by Western blot to confirm band disappearance

• Test for cross-reactivity with related proteins (other CNNM family members)

• Verify that detected protein has the expected molecular weight of approximately 96 kDa

• Consider using multiple antibodies targeting different epitopes of CNNM2

What are the optimal conditions for using CNNM2 antibodies in Western blot experiments?

For optimal Western blot results with CNNM2 antibodies:

• Sample preparation:

  • Use RIPA lysis buffer with protease inhibitor cocktail when preparing cell lysates

  • Denature samples in SDS sample reagent with 100 mM DTT for 30 minutes at 37°C (rather than boiling)

  • Consider separating membrane fractions using a native membrane protein extraction kit for studying membrane-localized CNNM2

• SDS-PAGE conditions:

  • Use 5-10% polyacrylamide gels depending on the resolution required

  • Load adequate protein amounts (typically 20-40 μg of total protein)

• Antibody concentrations:

  • Primary antibody concentration: 1.0 μg/ml for most CNNM2 antibodies

  • Secondary antibody dilution: typically 1:2000-1:5000

• Detection controls:

  • Use α-actin (1:30000) as loading control

  • Include Na⁺-K⁺ ATPase (1:1000) as a membrane fraction control when analyzing membrane expression

How should I optimize immunocytochemistry protocols with CNNM2 antibodies?

For optimal immunocytochemistry results:

• Cell preparation:

  • Seed cells on chamber slides and allow proper attachment

  • For transfection studies, use 0.5 μg of plasmid DNA and analyze after 24 hours

• Fixation and permeabilization:

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 in PBS for 1 hour

• Blocking and antibody incubation:

  • Block with 1% BSA in PBST for 30 minutes

  • Use CNNM2 primary antibody at 1:200 dilution

  • Apply fluorescent-conjugated secondary antibodies (e.g., Alexa Fluor 488) at 1:200-1:500 dilution

  • Include DAPI (5 μg/ml) for nuclear staining for 5 minutes

• Visualization:

  • Capture images using confocal or fluorescence microscopy

  • For membrane localization studies, focus on cellular periphery where CNNM2 is typically localized

How can I design experiments to investigate CNNM2's role in magnesium transport?

CNNM2's role in magnesium transport can be studied through these approaches:

• Stable isotope uptake assays:

  • Use the stable ²⁵Mg²⁺ isotope to track magnesium movement in cells

  • Transfect cells with wild-type or mutant CNNM2 constructs

  • Compare baseline ²⁵Mg²⁺ content (approximately 10% of total intracellular Mg²⁺) with uptake after incubation in ²⁵Mg²⁺-containing buffer

  • Measure uptake at multiple time points (5 minutes is optimal for capturing the exponential phase)

• Channel inhibitor studies:

  • Apply specific inhibitors during uptake assays to identify involved channels:

    • 2-APB (TRPM7 inhibitor)

    • Ouabain (Na⁺-K⁺-ATPase blocker)

    • Quinidin (SLC41A1 inhibitor)

    • Nitrendipin (MagT1 inhibitor)

  • The IC₅₀ of 2-APB inhibition for CNNM2-dependent Mg²⁺ uptake is 22 μM

• Magnesium efflux assays:

  • Use fluorescent indicators like Mag-green to measure intracellular Mg²⁺ levels

  • Compare efflux rates between cells expressing wild-type vs. mutant CNNM2

• Concentration-dependent kinetics:

  • Perform experiments at different Mg²⁺ concentrations (0.5-5 mM)

  • The highest CNNM2-dependent ²⁵Mg²⁺ uptake occurs between 1-2 mM, suggesting a Kₘ of approximately 0.5 mM

What experimental approaches can assess the impact of CNNM2 mutations found in patients?

To assess CNNM2 mutations:

• Expression and localization studies:

  • Compare membrane expression of wild-type vs. mutant CNNM2 through Western blotting of membrane fractions

  • Visualize protein localization using immunocytochemistry

  • Assess protein stability and degradation rates using cycloheximide chase assays

• Functional assays:

  • Perform ²⁵Mg²⁺ uptake assays comparing wild-type and mutant CNNM2

  • Measure intracellular Mg²⁺ concentrations using fluorescent indicators

  • Assess Mg²⁺ efflux capacity in cells expressing mutant vs. wild-type CNNM2

• Molecular modeling:

  • Generate structural models of mutations using templates like resolved structures of human CNNM-PRL complex (PDB code: 5LXQ)

  • Apply CHARMm force field followed by energy minimization using smart algorithms

  • Analyze potential disruptions to protein-protein interactions or ATP-Mg²⁺ binding

• Animal models:

  • Use zebrafish knockdown models to assess developmental and neurological phenotypes

  • Attempt rescue with wild-type vs. mutant CNNM2 cRNA

  • Measure body Mg²⁺ content as an indicator of systemic effects

How can I resolve contradictory findings about CNNM2's function as a magnesium transporter?

The literature contains conflicting reports about whether CNNM2 functions directly as a Mg²⁺ transporter. To address these contradictions:

• Experimental system considerations:

  • Different results have been obtained in various expression systems (Xenopus oocytes vs. mammalian cells)

  • CNNM2 may function differently depending on the cellular context and expression level

• Direct vs. indirect mechanisms:

  • Some studies suggest CNNM2 increases cellular Mg²⁺ uptake through regulation of TRPM7 rather than direct transport

  • Others propose CNNM2 is not a Mg²⁺ transporter per se but a regulatory protein involved in Mg²⁺ homeostasis

• Technical approach comparison:

  • Compare results from different methodologies:

    • Isotope uptake studies (²⁵Mg²⁺)

    • Electrophysiological measurements (patch-clamp analysis)

    • Fluorescent indicator-based assays

• Isomorph-specific effects:

  • Investigate both CNNM2 isomorphs (Iso1 and Iso2) separately

  • Different isomorphs exhibit distinct patterns of cellular distribution and interactor spectra

  • The spectrum of potential interactors of Iso1 is ten times smaller than that of Iso2

How can CNNM2 antibodies be used to study protein-protein interactions?

CNNM2 antibodies can be valuable tools for investigating protein-protein interactions through:

• Co-immunoprecipitation (Co-IP):

  • Use anti-CNNM2 antibodies to pull down CNNM2 and associated proteins

  • Apply stringent washing conditions to identify strong interactions

  • Analyze precipitates by mass spectrometry to identify novel interactors

  • Verify interactions by reverse Co-IP with antibodies against suspected interactors

• Proximity ligation assay (PLA):

  • Use CNNM2 antibodies in combination with antibodies against potential interactors

  • PLA signal indicates proteins are within 40 nm of each other, suggesting interaction

  • This approach can detect interactions in situ without cell disruption

• FRET/BRET analysis:

  • Combine antibody-based detection with fluorescent or bioluminescent reporters

  • Monitor dynamic interactions in living cells

• Pull-down assays with tagged proteins:

  • Use Strep-tagged CNNM2 constructs with Strep-Tactin resin for purification

  • Apply anti-CNNM2 antibodies for detection in subsequent Western blots

  • Elute with D-desthiobiotin at 2.5 mM final concentration

What are the key considerations when selecting CNNM2 antibodies for studying disease mechanisms?

When selecting CNNM2 antibodies for disease research:

• Epitope location considerations:

  • Choose antibodies that target regions unaffected by disease-causing mutations

  • For CBS domain mutations, select antibodies targeting N-terminal or transmembrane domains

  • Consider using antibodies targeting different epitopes to compare detection efficiency

• Isoform specificity:

  • Determine which CNNM2 isoforms are relevant to your disease model

  • Select antibodies that can distinguish between isoforms if needed

  • Verify that the antibody recognizes the species-specific isoform in your model system

• Validation in disease contexts:

  • Confirm antibody performance in disease-relevant tissues or cells

  • Verify that disease-associated modifications don't affect antibody recognition

  • Test antibody performance with both wild-type and mutant forms of CNNM2

• Cross-reactivity assessment:

  • Evaluate potential cross-reactivity with other CNNM family members

  • Particularly important when studying tissues expressing multiple CNNM proteins

  • Western blot analysis can help confirm specificity based on molecular weight differences

What are common issues when using CNNM2 antibodies and how can they be resolved?

Common issues and solutions include:

• Low signal intensity:

  • Increase antibody concentration (start with 2x recommended concentration)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use signal enhancement systems (e.g., biotin-streptavidin)

  • For Western blots, increase protein loading to 40-60 μg

• High background:

  • Increase blocking time and concentration (5% milk/BSA for 2 hours)

  • Add 0.1-0.3% Tween-20 to wash buffers

  • Pre-absorb antibody with non-specific proteins

  • Reduce secondary antibody concentration

• Multiple bands in Western blot:

  • Verify molecular weight (expected ~96 kDa for full-length CNNM2)

  • Use fresh protease inhibitors during sample preparation

  • Try different detergents for membrane protein extraction

  • Consider potential post-translational modifications or splice variants

• Poor subcellular localization:

  • Optimize fixation protocol (test paraformaldehyde vs. methanol)

  • Adjust permeabilization conditions

  • Use mitochondrial markers (MitoTracker Green FM or COXIV antibodies) for colocalization studies

  • Compare with published localization patterns

How can I design controls to validate findings from CNNM2 antibody-based experiments?

Proper controls for CNNM2 antibody experiments:

• Genetic controls:

  • CNNM2 knockdown (siRNA/shRNA)

  • CNNM2 knockout (CRISPR-Cas9)

  • Overexpression of tagged CNNM2 constructs

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be reduced/eliminated if antibody is specific

  • Use unrelated peptide as negative control

• Cell/tissue type controls:

  • Include samples with known high expression (kidney, brain)

  • Include samples with low/no expression as negative controls

  • Compare with published expression patterns

• Technical controls:

  • Secondary antibody-only control

  • Isotype control antibody

  • Multiple CNNM2 antibodies targeting different epitopes

When analyzing CNNM2 in Mg²⁺-responsive cell systems, what factors affect experimental reproducibility?

Factors affecting reproducibility in Mg²⁺-responsive systems:

• Magnesium variability:

  • Monitor and control Mg²⁺ levels in culture media

  • Use Mg²⁺-free HBSS supplemented with dialyzed FBS (10%)

  • Account for Mg²⁺ in FBS and other supplements

  • Standardize the duration of Mg²⁺ starvation periods (0.5, 1, 2, 4, 8, 24 hours)

• CNNM2 expression regulation:

  • CNNM2 expression is regulated by Mg²⁺ availability

  • Response to Mg²⁺ starvation varies by cell type (more pronounced in lymphoblasts than T-lymphocytes)

  • Allow consistent time for expression after transfection (typically 24 hours)

• Cell-specific factors:

  • Choose appropriate cell models (HEK293, DCT cells)

  • Account for endogenous CNNM2 expression levels

  • Consider expression of other magnesium transporters and channels

• Measurement technique standardization:

  • For stable isotope studies, standardize uptake duration and washing steps

  • For fluorescent indicators, maintain consistent dye loading and calibration

  • For Western blots, use ratio comparisons with consistent loading controls